2018年9月第38卷第9期中国实用内科杂志813
CochraneDatabaseSystRev,2009(1):CD000067.[138]XieY,ZhuW,LiN,etal.Theoutcomeofinitialpercutaneousdrainage
[120],,,.versussurgicaldrainageforintra-abdominalabscessesinCrohn''s
高翔肖英莲陈旻湖等硫唑嘌呤治疗活动性克罗恩病的
开放性前瞻性研究[J].中华消化杂志,2011,31(3):145-149.disease[J].IntJColorectalDis,2012,27(2):199-206.
[121]FeaganBG,FedorakRN,IrvineEJ,etal.Acomparisonofmethotrexate[139]BernellO,LapidusA,HellersG.Riskfactorsforsurgeryandrecurrence
withplaceboforthemaintenanceofremissioninCrohn’sdisease.in907patientswithprimaryileocaecalCrohn’sdisease[J].BrJSurg,
NorthAmericanCrohn’sStudyGroupInvestigators[J].NEnglJMed,2000,87(12):1697-1701.
2000,342(22):1627-1632.[140]SacharDB,LemmerE,IbrahimC,etal.Recurrencepatternsafterfirst
[122]PatelV,MacdonaldJK,McDonaldJW,etal.MethotrexateforresectionforstricturingorpenetratingCrohn’sdisease[J].Inflamm
maintenanceofremissioninCrohn’sdisease[J].CochraneDatabaseBowelDis,2009,15(7):1071-1075.
SystRev,2009(4):CD006884.[141]GaoX,YangRP,ChenMH,etal.Riskfactorsforsurgeryand
[123]Sch?lmerichJ,FellermannK,SeiboldFW,etal.Arandomised,double-postoperativerecurrence:analysisofasouthChinacohortwith
blind,placebo-controlledtrialoftrichurissuisovainactiveCrohn’sCrohn’sdisease[J].ScandJGastroenterol,2012,47(10):1181-1191.
disease[J].JCrohnsColitis,2017,11(4):390-399.[142]ReeseGE,NanidisT,BorysiewiczC,etal.Theeffectofsmokingafter
[124]LewisJD,SchwartzJS,LichtensteinGR.AzathioprineformaintenancesurgeryforCrohn’sdisease:ameta-analysisofobservationalstudies[J].
ofremissioninCrohn’sdisease:benefitsoutweightheriskofIntJColorectalDis,2008,23(12):1213-1221.
lymphoma[J].Gastroenterology,2000,118(6):1018-1024.[143]ArdizzoneS,MaconiG,SampietroGM,etal.Azathioprineand
[125]丁辉,钱家鸣,单科曙.硫唑嘌呤治疗炎症性肠病的不良反应mesalamineforpreventionofrelapseafterconservativesurgeryfor
[J].,2011,23(1):40-42,47.Crohn’sdisease[J].Gastroenterology,2004,127(3):730-740.
分析临床消化病杂志
[126]张芳宾,丁亮,李高翔,等.硫嘌呤甲基转移酶基因型和酶活[144]Peyrin-BirouletL,DeltenreP,ArdizzoneS,etal.Azathioprineand
[J].,6-mercaptopurineforthepreventionofpostoperativerecurrencein
性检测在炎症性肠病治疗中的临床价值中华消化杂志
2010,30(7):436-440.Crohn’sdisease:ameta-analysis[J].AmJGastroenterol,2009,104(8):
[127]CaoQ,ZhuQ,ShangY,etal.Thiopurinemethyltransferasegene2089-2096.
polymorphismsinChinesepatientswithinflammatorybowel[145]RutgeertsP,VanAsscheG,VermeireS,etal.Ornidazolefor
disease[J].Digestion,2009,79(1):58-63.prophylaxisofpostoperativeCrohn’sdiseaserecurrence:arandomized,
[128]AsadaA,NishidaA,ShioyaM,etal.NUDT15R139C-relateddouble-blind,placebo-controlledtrial[J].Gastroenterology,2005,
thiopurineleukocytopeniaismediatedby6-thioguaninenucleotide-128(4):856-861.
independentmechanisminJapanesepatientswithinflammatorybowel[146]D’HaensGR,VermeireS,VanAsscheG,etal.Therapyof
disease[J].JGastroenterol,2016,51(1):22-29.metronidazolewithazathioprinetopreventpostoperativerecurrence
[129]ChaoK,WangX,CaoQ,etal.CombineddetectionofNUDT15ofCrohn’sdisease:acontrolledrandomizedtrial[J].Gastroenterology,
variantscouldhighlypredictthiopurine-inducedleukopeniainChinese2008,135(4):1123-1129.
patientswithinflammatoryboweldisease:amulticenteranalysis[J].[147]YoshidaK,FukunagaK,IkeuchiH,etal.Scheduledinfliximab
InflammBowelDis,2017,23(9):1592-1599.monotherapytopreventrecurrenceofCrohn’sdiseasefollowing
[130]YanaiH,HanauerSB.Assessingresponseandlossofresponsetobiologicalileocolicorilealresection:a3-yearprospectiverandomizedopen
therapiesinIBD[J].AmJGastroenterol,2011,106(4):685-698.trial[J].InflammBowelDis,2012,18(9):1617-1623.
[131]D’HaensGR,PanaccioneR,HigginsPD,etal.TheLondonPosition[148]DignassA,VanAsscheG,LindsayJO,etal.ThesecondEuropean
StatementoftheWorldCongressofGastroenterologyonBiologicalevidence-basedConsensusonthediagnosisandmanagementof
TherapyforIBDwiththeEuropeanCrohn’sandColitisOrganization:Crohn’sdisease:Currentmanagement[J].JCrohn’sColitis,2010,
whentostart,whentostop,whichdrugtochoose,andhowtopredict4(1):28-62.
response[J].AmJGastroenterol,2011,106(2):199-212;quiz213.[149]VanAsscheG,MangusoF,ZibelliniM,etal.Oralprolongedrelease
[132]SandbornWJ,FazioVW,FeaganBG,etal.AGAtechnicalreviewonbeclomethasonedipropionateandprednisoneinthetreatmentof
perianalCrohn’sdisease[J].Gastroenterology,2003,125(5):1508-activeulcerativecolitis:resultsfromadouble-blind,randomized,
1530.parallelgroupstudy[J].AmJGastroenterol,2015,110(5):708-715.
[133]RicartE,SandbornWJ.Infliximabforthetreatmentoffistulasinpatients[150]PanésJ,García-OlmoD,VanAsscheG,etal.Expandedallogeneic
withCrohn’Sdisease[J].Gastroenterology,1999,117(5):1247-1248.adipose-derivedmesenchymalstemcells(Cx601)forcomplex
[134]SandsBE,AndersonFH,BernsteinCN,etal.InfliximabmaintenanceperianalfistulasinCrohn’sdisease:aphase3randomised,double-blind
therapyforfistulizingCrohn’sdisease[J].NEnglJMed,2004,350(9):controlledtrial[J].Lancet,2016,388(10051):1281-1290.
876-885.[151]何瑶,陈瑜君,杨红,等.回结肠克罗恩病与肠结核临床及内
[135]YamamotoT,FazioVW,TekkisPP.Safetyandefficacyofstricture[J].,2012,29(6):325-328.
镜特征比较中华消化内镜杂志
plastyforCrohn’sdisease:asystematicreviewandmeta-analysis[J].[152]高翔,何瑶,陈瑜君,等.试验性抗结核治疗鉴别肠结核与
DisColonRectum,2007,50(11):1968-1986.[J].,2011,
克罗恩病的临床与内镜分析中华消化内镜杂志
[136]HassanC,ZulloA,DeFrancescoV,etal.Systematicreview:28(8):446-451.
EndoscopicdilatationinCrohn’sdisease[J].AlimentPharmacolTher,[153]HeY,ChenYJ,ChenBL,etal.Thevalueofempiricanti-tuberculosis
2007,26(11-12):1457-1464.therapyinthedifferentialdiagnosisbetweenintestinaltuberculosis
[137]FeaginsLA,HolubarSD,KaneSV,etal.CurrentstrategiesintheandCrohn’sdiseaseinChina[J].InternJClinExperiMed,2016,
managementofintra-abdominalabscessesinCrohn’sdisease[J].Clin9(6):9278-9285.
GastroenterolHepatol,2011,9(10):842-850.
2018-05-30收稿本文编辑：颜廷梅 |
|
